J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miller, V.
Right arrow Articles by Hurt, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miller, V.
Right arrow Articles by Hurt, R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

Plasma nitric oxide before and after smoking cessation with nicotine nasal spray

VM Miller, DA Lewis, KS Rud, KP Offord, IT Croghan, and RD Hurt

Nicotine may affect cardiovascular function through release of neurotransmitters from autonomic nerves or release of vasoactive substances from the vascular endothelium. Nitric oxide is a neurotransmitter and endothelium-derived factor that reduces tone of vascular smooth muscle. Experiments were designed to determine whether or not use of nicotine nasal spray for smoking cessation affects plasma levels of nitric oxide. Forty smokers self-administered nicotine by nasal spray (one 0.5 mg spray to each nostril). Blood samples were taken before the use of the nasal spray and at treatment day 7 for the measurement of cotinine by high pressure liquid chromatography and nitric oxide (NOx) by chemiluminescence. Age-comparable controls were never-smokers nonnicotine users recruited from laboratory personnel. Mean plasma concentrations of NOx from smokers before treatment were significantly greater compared with nonsmokers (23 +/- 10, n = 40 and 15 +/- 6, n = 13 nmoles/mL [mean +/- SD], respectively, P < 0.01). Plasma NOx in smokers was not significantly correlated with the average daily number of cigarettes smoked (r2 = 0.02, P > 0.05) but was positively and linearly correlated with plasma cotinine (r2 = 0.13, P < 0.02). In 32 self-reported abstinent smokers (confirmed by expired carbon monoxide < 9 ppm) using nicotine nasal spray, cotinine decreased by 64% from pretreatment levels of 284 +/- 103 to posttreatment levels of 90 +/- 58 ng/mL. Plasma NOx was unchanged and went from 23.0 +/- 10.1 at pretreatment to 21 +/- 12 nmoles/mL with nicotine treatment. These results suggest that nicotine-use, independent of cigarette smoking, affects plasma NOx.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
ChestHome page
C. Brindicci, K. Ito, O. Torre, P. J. Barnes, and S. A. Kharitonov
Effects of Aminoguanidine, an Inhibitor of Inducible Nitric Oxide Synthase, on Nitric Oxide Production and Its Metabolites in Healthy Control Subjects, Healthy Smokers, and COPD Patients
Chest, February 1, 2009; 135(2): 353 - 367.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
C. V. Remillard, D. D. Tigno, O. Platoshyn, E. D. Burg, E. E. Brevnova, D. Conger, A. Nicholson, B. K. Rana, R. N. Channick, L. J. Rubin, et al.
Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension
Am J Physiol Cell Physiol, May 1, 2007; 292(5): C1837 - C1853.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
L. M. A. Heunks, M. J. Cody, P. C. Geiger, P. N. R. Dekhuijzen, and G. C. Sieck
Nitric oxide impairs Ca2+ activation and slows cross-bridge cycling kinetics in skeletal muscle
J Appl Physiol, November 1, 2001; 91(5): 2233 - 2239.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
B. H. Tonnessen, S. R. Severson, R. D. Hurt, and V. M. Miller
Modulation of Nitric-Oxide Synthase by Nicotine
J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 601 - 606.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
V. M. Miller, W. D. Clouse, B. H. Tonnessen, U. S. Boston, S. R. Severson, S. Bonde, K. S. Rud, and R. D. Hurt
Time and dose effect of transdermal nicotine on endothelial function
Am J Physiol Heart Circ Physiol, October 1, 2000; 279(4): H1913 - H1921.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
W. D. Clouse, H. Yamaguchi, M. R. Phillips, R. D. Hurt, L. A. Fitzpatrick, T. P. Moyer, C. Rowland, H. V. Schaff, and V. M. Miller
Effects of transdermal nicotine treatment on structure and function of coronary artery bypass grafts
J Appl Physiol, September 1, 2000; 89(3): 1213 - 1223.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American College of Clinical Pharmacology